Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Inflammatory Bowel Diseases: A Pilot Study

Life, Journal Year: 2024, Volume and Issue: 14(10), P. 1226 - 1226

Published: Sept. 25, 2024

Inflammatory bowel disease (IBD) is characterized by persistent inflammation and often associated with metabolic dysfunction-associated steatotic liver (MASLD). IBD patients are at risk of developing MASLD due to shared factors such as gut dysbiosis systemic inflammation. The new nomenclature emphasizes the link between steatosis cardiometabolic comorbidities. However, prevalence in remains poorly explored. main aim this cross-sectional study assess ultrasound (US) clinical features IBDs.

Language: Английский

---

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease

Antioxidants, Journal Year: 2024, Volume and Issue: 13(11), P. 1386 - 1386

Published: Nov. 14, 2024

Background: The gut microbiota constitutes a complex microorganism community that harbors bacteria, viruses, fungi, protozoa, and archaea. human bacterial has been extensively proven to participate in metabolism, immunity, nutrient absorption. Its imbalance, namely “dysbiosis”, linked disordered metabolism. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the features deranged metabolism leading cause cirrhosis hepatocellular carcinoma. Thus, there pathophysiological link between dysbiosis MASLD. Aims Methods: We aimed review literature data on composition its MASLD describe concept “gut–liver axis”. Moreover, we reviewed approaches for modulation treatment. Results: There consolidated evidence particular associated with stages. model explaining relationship bidirectional organization, physiopathology Oxidative stress keystones pathophysiology fibrosis generation. promising efficacy pre- probiotics reversing patients, therapeutic effects. Few yet encouraging fecal transplantation (FMT) are available literature. Conclusions: characteristic key target reversal treatment via diet, pre/probiotics, FMT remains treatment, prevention, reversal.

Language: Английский

---

Gut microbiota: the pathogenetic bridge between inflammatory bowel disease and metabolic-associated steatotic liver disease

Expert Review of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 4

Published: Feb. 5, 2025

Language: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease vs. Metabolic Dysfunction-Associated Fatty Liver Disease: Which Option is the Better Choice?

British Journal of Hospital Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 5

Published: Feb. 11, 2025

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of chronic and linked to metabolic syndrome components such as insulin resistance obesity. In 2020, the term "metabolic dysfunction-associated (MAFLD)" was introduced, incorporating risk factors including patients with other conditions. However, concerns about "fatty" led proposal steatotic (MASLD)", which refined diagnostic criteria but excluded significant alcohol consumption or comorbidities. Although MASLD improves NAFLD in some respects, its exclusion comorbid conditions may hinder comprehensive care for dysregulation. A proposed solution "combinatorial MASLD", would better address Further studies are necessary determine most appropriate nomenclature clinical practice.

Language: Английский

---

Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population‐based study

MedComm, Journal Year: 2025, Volume and Issue: 6(2)

Published: Feb. 1, 2025

Abstract We aimed to compare the association of metabolic dysfunction‐associated fatty liver disease (MAFLD), steatotic (MASLD), alcohol‐related (ALD), dysfunction and ALD (MetALD), MASLD with viral hepatitis (MASLD‐Viral) risks cirrhosis, cancer, mortality. The data 464,556 adults from UK Biobank (UKB), 13,526 National Health Nutrition Examination Survey (NHANES), 2554 BeijngFH Cohort Study (FHCS) were included. Adjusted hazard ratios (aHR) odds calculated using Cox Logistic regression models, respectively. Compared non‐SLD, risk cancer increased MetALD (aHR 1.70 [95% CI 1.37, 2.09]), (1.91 [1.66, 2.21]), MAFLD (2.01 [1.76, 2.29]), (3.16 [2.54, 3.93]), MASLD‐Viral (22.0 [10.8, 44.4]) in a stepwise manner UKB; all‐cause mortality MetALD, MASLD, MAFLD, ALD, NHANES. ratio fibrosis FHCS. In patients diabetes, metformin plus other drugs associated higher or MAFLD. Prevention rather than antiglycemic treatment is important for diabetic

Language: Английский

---

Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(9), P. 2973 - 2973

Published: April 25, 2025

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in inflammatory bowel (IBD) patients due to chronic inflammation and metabolic disturbances. However, reliable non-invasive biomarkers for MASLD prediction this population are lacking. This study evaluated the predictive value of scores lipid ratios onset IBD patients. Methods: An observational retrospective was conducted on 358 at “Renato Dulbecco” Teaching Hospital Catanzaro, Italy, a period between 1 January 2021 31 December 2024. Clinical laboratory data, including ratios, were analyzed using chi-square Kruskal–Wallis tests as appropriate. Post hoc comparisons Dunn’s test. Receiver operating characteristic analysis assessed their accuracy MASLD. p < 0.05 considered significant. Results: IBD-MASLD had significantly higher body mass index (BMI, 27 ± 4 vs. 22 2 kg/m2; 0.001), waist circumference (100 11 85 cm; other anthropometric parameters, scores, than IBD-only The score insulin resistance [METS-IR, area under curve (AUC = 0.754)] 0.754) exhibited highest accuracy, followed by accumulation product (LAP, AUC 0.737), BMI 0.709), triglyceride/high-density lipoprotein (TG/HDL, 0.701). Insulin homeostasis model assessment 0.680) triglyceride-glucose 0.674), moderate use. visceral adiposity 0.664) low-density lipoprotein/high-density 0.656) showed lower discriminative ability, while fibrosis-4 0.562) weakest diagnostic performance. Conclusions: Our findings suggest that primarily driven cardiometabolic dysfunction. introduction METS-IR, LAP, TG/HDL into clinical assessments could prove useful preventing cardiovascular complications setting.

Language: Английский

---

Examining the Relationship Between Persistent Organic Pollutants and Metabolic-Associated Fatty Liver Disease: A Cross-Sectional Analysis Using NHANES Data

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 28, 2025

Recently, the term Metabolic-Associated Fatty Liver Disease (MAFLD) has been adopted to better reflect underlying pathology and association with metabolic issues. Beyond dietary factors physical activity, previous studies have suggested that persistent organic pollutants (POPs), may contribute etiology of MAFLD; however, this disease can also develop at very low POP exposure levels, making it challenging discern their specific effect. This study aims investigate potential link between POPs, prevalence MAFLD. Data from National Health Nutrition Examination Survey (NHANES) was utilized for cross-sectional study. Participants were categorized based on MAFLD status levels various POPs measured in blood serum. Cox regression estimate adjusted ratio (aPR) used. Hazard Index (HI), Proportion Maximum Scaling (POMS), Toxicity Burden (TBI) applied assess mixtures. A total 4,224 participants included, 47 (33–65) years, 53.0% women, 50.1% had No significant sex differences observed main analysis regarding individual prevalence. However, sensitivity analyses revealed an inverse relationship certain prevalence, particularly women. Higher PCBs associated a lower highlighted effects pollutants, mixtures, sex-specific differences. The combined use HI, POMS, TBI provided more detailed risk assessment. Findings suggest biological stressors play roles how influence MAFLD, warranting further investigation into mechanisms health outcomes different ranges.

Language: Английский

---

Metabolic dysfunction-associated steatotic liver disease and diabetes: the cross-talk between hepatologist and diabetologist

Expert Review of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 18(8), P. 431 - 439

Published: Aug. 2, 2024

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (DM) are the most prevalent metabolic disorders globally. The numbers affected in both also rapidly increasing with alarming trends children young adults.

Language: Английский

---

Evaluation of Nomenclature of Fatty Liver Disease in Association with Hepatocellular Carcinoma: A 15.5-Year Cohort Study in Korea

Published: Jan. 1, 2024

Language: Английский

---

Sarcopenia and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review

Published: Aug. 8, 2024

The fundamental goal of modern medicine is to increase human life expectancy. Currently, most the patients in hospitals with different clinical profiles are elderly and senile subjects, a high incidence comorbidities, as well concomitant age-related changes peripheral tissues. One such change sarcopenia, progressive loss muscle mass, strength, function that associated risk adverse outcomes, leading an increased disability death among older adults. mechanisms development sarcopenia currently being actively studied. This narrative review presents issues epidemiology, pathophysiology, diagnostic criteria for sarcopenia. relationships between metabolic dysfunction-associated steatotic liver disease (MASLD) possible promising directions treatment this comorbid pathology considered.

Language: Английский

---